AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 231 min read$TNGX

Tango Therapeutics, Inc. (TNGX) Posts 82% ORR in 2L/3L PDAC; Plans Front-Line Phase 3 in 1H27

Tango Therapeutics reported 82% ORR in 2L/3L PDAC patients using vopimetostat + daraxonrasib, with median PFS not yet reached. The company plans a Phase 3 trial for front-line PDAC in 1H 2027, according to the press release.

Original reporting
tradingview.com
Published Oct 23, 2026, 10:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 10:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tango Therapeutics, Inc. (TNGX) Posts 82% ORR in 2L/3L PDAC; Plans Front-Line Phase 3 in 1H27 — source image
Source · tradingview.com
Decision brief

The 30-second read

$TNGXBullishHigh
01

Why it matters

The data positions the company for a pivotal Phase 3 trial, potentially unlocking significant valuation upside.

02

Market read

First‑report of strong Phase 2b results for a niche pancreatic cancer indication.

03

What to watch

Regulatory timeline and competitive landscape for MTAP‑deleted PDAC treatments.

Relevance 8/10Novelty 9/10Timing: today

Background

Tango Therapeutics is a clinical‑stage biotech focused on epigenetic therapies.

Company-level read

Ticker impact

$TNGXBullishHigh confidence
Context

Tango Therapeutics disclosed 82% ORR and 88% 9‑month PFS in a Phase 2b trial for MTAP‑deleted/RAS‑mutant PDAC.

Expected impact

likely upward pressure as investors price in the positive trial readout

Evidence & confidence

Phase 2b data with high response rates are material for a biotech and often trigger price appreciation ahead of a Phase 3 launch.

Market effects

Sector

May boost sentiment for oncology and MTAP‑targeted therapies.

Regional

Limited to US biotech investors.

Global

Potential interest from global oncology investors.

Counterpoint

What could challenge this read

If the Phase 3 fails to replicate, the stock could sharply reverse.

Key entities

  • company
    Tango Therapeutics, Inc.

    Biotech developer of vopimetostat + daraxonrasib.

Read at source← All news

StoryTango Therapeutics reports 82% response rate and 88% nine‑month progression‑free survival in pancreatic cancer trial

Also covered by

1 outlet

Related articles

OCT 23
$TNGXHighAI 8/10

Why is Tango Therapeutics stock sliding today?

Tango Therapeutics (TNGX) fell 6.8% in pre-market trading after releasing Phase 1/2 trial results showing 82% response rate and 88% progression-free survival in pancreatic cancer patients. The decline follows a 28% stock surge ahead of the data release and coincides with broader market sell-offs. An affiliate officer's planned share sale also contributed to pressure.

investing.com1 min
OCT 23
$TNGXMedAI 8/10

Tango Therapeutics reports pancreatic cancer trial data

Tango Therapeutics (TNGX) reported Phase 1/2 trial data for vopimetostat in pancreatic and lung cancer. The study showed an 82% response rate in pancreatic cancer patients, with a 9-month progression-free survival rate of 88%. The combination was well-tolerated. Tango plans a Phase 3 trial in 2027. Vopimetostat is an investigational PRMT5 inhibitor.

investing.com2 min
OCT 23
$TNGXMedAI 8/10

Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy 82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% i

SEC EDGAR 8-K2 min
OCT 20
$TNGXMedAI 8/10

Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In?

Tango Therapeutics (TNGX) reported a 92% response rate in a small pancreatic cancer trial using vopimetostat and daraxonrasib. The company plans late-stage testing, but commercial success depends on larger trial results. TNGX has $1B in cash and no current revenue. Analysts have mixed price targets, and hedge fund interest is growing. The stock's valuation hinges on future clinical milestones.

insidermonkey.com2 min